Development of Peptoid-Based Heteroaryl-Decorated Histone Deacetylase (HDAC) Inhibitors with Dual-Stage Antiplasmodial Activity

10 April 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Malaria remains a significant global health challenge, causing approximately 608,000 deaths and over 249 million infections in 2022. With the rise of resistance to current chemotherapies, including artemisinin-based combination therapies (ACTs), the search for novel antimalarial drugs with new modes of action is of utmost importance. Histone deacetylases (HDACs) have been identified as promising targets for antiplasmodial drug development. In this study, we present a novel series of peptoid-based HDAC inhibitors incorporating heteroaryl residues, synthesized via an efficient multicomponent protocol. The subsequent screening of 16 compounds from our mini-library identified 6i as the most promising candidate, demonstrating potent activity against asexual blood-stage parasites (IC50 Pf3D7 = 30 nM; IC50 PfDd2 = 98 nM), low submicromolar activity against liver-stage parasites (IC50 PbEEF = 0.25 µM), excellent microsomal stability (t1/2 > 60 min), and negligible cytotoxicity to HepG2 cells (IC50 > 10 µM).


Histone deacetylase
HDAC inhibitors
multicomponent reaction

Supplementary materials

Supporting Information
1H and 13 NMR spectra, HPLC traces


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.